FDA approves drug to treat relapsed FLSeptember 15, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Immune status linked to outcomes of CAR T-cell therapySeptember 15, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersALLNon-Hodgkin LymphomaAggressive Lymphomas
Survey reveals lack of specialized care for AYAs with cancerSeptember 15, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersHematology Nursing
Report details progress, obstacles in cancer research and careSeptember 14, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPediatricsRelated IssuesAMLALL
FDA grants priority review for drug to treat APLSeptember 14, 2017Leukemia, Myelodysplasia, TransplantationPharmacy
R&D costs for cancer drugs may be lower than previously thoughtSeptember 13, 2017PharmacyRelated Issues
Biosimilar deemed equivalent to reference drug in FLSeptember 12, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Treatment for WDTC tied to increased risk of AMLSeptember 12, 2017Leukemia, Myelodysplasia, TransplantationAML
Study: Many cancer patients don’t understand clinical trialsSeptember 11, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaRelated Issues
CCSs have higher burden of chronic conditionsSeptember 9, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAMLALLHodgkin LymphomaNon-Hodgkin LymphomaAggressive Lymphomas